Related Experiment Videos

Macrolides for diffuse panbronchiolitis

Ming Yang1, Bi Rong Dong, Jing Lu

  • 1Department of Geriatrics, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.

The Cochrane Database of Systematic Reviews
|December 15, 2010
PubMed
Abstract

Insights

Limited evidence supports macrolide antibiotics for diffuse panbronchiolitis (DPB). One small study showed potential benefits, but more high-quality research is needed to confirm macrolide efficacy and safety in DPB treatment.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Diffuse panbronchiolitis (DPB) is a chronic airway disease primarily affecting East Asian populations.
  • Macrolides are commonly used for DPB, but evidence is mainly from non-randomized studies.

Purpose of the Study:

  • To evaluate the efficacy and safety of macrolide antibiotics for treating DPB.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and quasi-RCTs.
  • Searched multiple databases including CENTRAL, MEDLINE, EMBASE, CBM, CNKI, KoreaMed, and Japana Centra Revuo Medicina.
  • Assessed study quality and risk of bias; analyzed outcomes including survival, lung function, and clinical response using risk ratios and 95% confidence intervals.

Main Results:

  • Only one small RCT (19 participants) with methodological limitations was included.
  • The study indicated improvement in CT scan images for all participants receiving long-term, low-dose erythromycin.
  • Control group participants showed worsening or unchanged CT scan images; adverse effects were not reported.

Conclusions:

  • Current evidence for macrolides in DPB treatment is scarce.
  • No new recommendations can be made due to limited data.
  • Current guidelines suggest using low-dose macrolides for at least six months post-diagnosis.

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...